NORTH PALM BEACH, FL / ACCESSWIRE / June 7, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focused in therapeutic monoclonal antibody space presented their Phase I Clinical Data at the American Society of Clinical Oncology (ASCO) meeting in Chicago in a poster presentation. The abstract may be viewed on the Company web site www.nascentbiotech.com. The data is also available at https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.2053.
"The presentation displayed our Phase I data, which included our safety data at various dose cohorts and early outcomes data, was well received and viewed by interested parties at the conference. In summary, it showed the drug to be very safe at 5 ascending dose cohorts and definitive bioactivity in several patients," stated Dr. Mini Gill who presented for the Company.
Nascent Biotech therapeutic antibody Pritumumab (PTB) is a natural human antibody. This monoclonal antibody targets cell surface Vimentin (ectodomain vimentin), shown to be expressed on the surface of epithelial cancers. PTB is a targeted immunotherapy that binds to the tumor via cell surface vimentin and recruits the host immune system to eliminate cancer cells.
About Nascent Biotech
Nascent Biotech, Inc. (OTCQB:NBIO) is a clinical-stage biotech company pioneering the development of human monoclonal antibodies to be used in the treatment of various cancers and viral infections, helping people worldwide. Its products are not yet commercially available. The Company's lead candidate, Pritumumab (PTB), is a human monoclonal Antibody (Mab) that is progressing to Phase 2 clinical trials for the treatment of Brain Cancer.
For further information please visit our website www.nascentbiotech.com.
Forward Looking Safe Harbor Statement
Statements in this press release about our future expectations constitute 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc's Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Corporate Contact
Clinical Trials
clinicaltrials@nascentbiotech.com
SOURCE: Nascent Biotech Inc.
View source version on accesswire.com:https://www.accesswire.com/759598/Nascent-Biotech-Phase-I-Clinical-Data-Presented-at-the-American-Society-of-Clinical-Oncology-Annual-Meeting
